this study is conducted to evaluate the role of the novel triple therapy combination in
reducing the mortality rate, reducing the shock time, and reversal of organ damage.
the study includes two arms, the first arm is the control which received hydrocortisone
monotherapy and the second arm is the intervention arm which received the triple therapy
regimen.
calculation of 28 days in-hospital mortality is the primary outcome. shock time, vasopressor
doses, infection markers, and organ function tests are the secondary outcomes.
the data will be analyzed by student t-test or Mann Whitney test, Fischer exact or chi-square
test for numbers, repeated measures ANOVA will be used to consider confounders and other
parameters, mortality will be expressed by Kaplan Meier and ROC curve.
For Multivariate analysis of repeated quantitative outcomes, linear mixed models were used to
quantify the relationship between one dependent variable (SOFA, SCr, doses of vasopressors)
and many independent variables including group type and sepsis phenotype adjusted to other
clinical and demographic factors.